NEW YORK, Oct 31 (Reuters) - Biotechnology company Genentech Inc (DNA.N: Quote, Profile, Research) is delaying a plan which would make it harder for doctors to use its cancer drug Avastin as an inexpensive treatment for eye afflictions, the Wall Street Journal reported on Wednesday.
